Skip to main content
Top
Published in: BMC Neurology 1/2022

Open Access 01-12-2022 | Insulins | Research

Association of β-cell function and cognitive impairment in patients with abnormal glucose metabolism

Authors: Mengyi Guo, Jiaokun Jia, Jia Zhang, Mingyue Zhou, Anxin Wang, Shengyun Chen, Xingquan Zhao

Published in: BMC Neurology | Issue 1/2022

Login to get access

Abstract

Background

Insulin has been demonstrated to play an important role in the occurrence and development of Alzheimer’s disease, especially in those with diabetes. β cells are important insulin-producing cells in human pancreas. This study aimed to investigate the association between β-cell dysfunction and cognitive impairment among patients over 40-year-old with abnormal glucose metabolism in Chinese rural communities.

Methods

A sample of 592 participants aged 40 years or older from the China National Stroke Prevention Project (CSPP) between 2015 and 2017 were enrolled in this study. Abnormal glucose metabolism was defined when hemoglobin Alc ≥ 5.7%. Cognitive function was assessed by the Beijing edition of the Montreal Cognitive Assessment scale. Homeostasis assessment of β-cell function was performed and classified into 4 groups according to the quartiles. A lower value of HOMA-β indicated a worse condition of β-cell function. Multivariate logistic regression was used to analyze the association between β-cell function and cognitive impairment.

Results

In a total of 592 patients with abnormal glucose metabolism, the average age was 60.20 ± 7.63 years and 60.1% patients had cognitive impairment. After adjusting for all potential risk factors, we found the first quartile of β-cell function was significantly associated with cognitive impairment (OR: 2.27, 95%CI: 1.32–3.92), especially at the domains of language (OR: 1.64, 95%CI: 1.01–2.65) and abstraction (OR: 2.29, 95%CI: 1.46–3.58).

Conclusions

Our study showed that worse β-cell function is associated with cognitive impairment of people over 40-year-old with abnormal glucose metabolism in Chinese rural communities, especially in the cognitive domains of abstraction and language.
Literature
1.
go back to reference Joe E, Ringman JM. Cognitive symptoms of Alzheimer's disease: clinical management and prevention. BMJ. 2019;367:l6217.PubMedCrossRef Joe E, Ringman JM. Cognitive symptoms of Alzheimer's disease: clinical management and prevention. BMJ. 2019;367:l6217.PubMedCrossRef
2.
go back to reference Trevisan K, Cristina-Pereira R, Silva-Amaral D, Aversi-Ferreira TA. Theories of aging and the prevalence of Alzheimer's disease. Biomed Res Int. 2019;2019:9171424.PubMedPubMedCentralCrossRef Trevisan K, Cristina-Pereira R, Silva-Amaral D, Aversi-Ferreira TA. Theories of aging and the prevalence of Alzheimer's disease. Biomed Res Int. 2019;2019:9171424.PubMedPubMedCentralCrossRef
3.
go back to reference Jia J, Wei C, Chen S, Li F, Tang Y, Qin W, et al. The cost of Alzheimer's disease in China and re-estimation of costs worldwide. Alzheimers Dement. 2018;14(4):483–91.PubMedCrossRef Jia J, Wei C, Chen S, Li F, Tang Y, Qin W, et al. The cost of Alzheimer's disease in China and re-estimation of costs worldwide. Alzheimers Dement. 2018;14(4):483–91.PubMedCrossRef
4.
go back to reference Lin SY, Lin PC, Lin YC, Lee YJ, Wang CY, Peng SW, et al. The clinical course of early and late mild cognitive impairment. Front Neurol. 2022;13:685636.PubMedPubMedCentralCrossRef Lin SY, Lin PC, Lin YC, Lee YJ, Wang CY, Peng SW, et al. The clinical course of early and late mild cognitive impairment. Front Neurol. 2022;13:685636.PubMedPubMedCentralCrossRef
5.
go back to reference Lotan R, Ganmore I, Livny A, Itzhaki N, Waserman M, Shelly S, et al. Effect of advanced glycation end products on cognition in older adults with type 2 diabetes: results from a pilot clinical trial. JAD. 2021;82(4):1785–95.PubMedCrossRef Lotan R, Ganmore I, Livny A, Itzhaki N, Waserman M, Shelly S, et al. Effect of advanced glycation end products on cognition in older adults with type 2 diabetes: results from a pilot clinical trial. JAD. 2021;82(4):1785–95.PubMedCrossRef
6.
go back to reference Zhang Z, Zhang B, Wang X, Zhang X, Yang QX, Qing Z, et al. Olfactory dysfunction mediates adiposity in cognitive impairment of type 2 diabetes: insights from clinical and functional neuroimaging studies. Diabetes Care. 2019;42(7):1274–83.PubMedCrossRef Zhang Z, Zhang B, Wang X, Zhang X, Yang QX, Qing Z, et al. Olfactory dysfunction mediates adiposity in cognitive impairment of type 2 diabetes: insights from clinical and functional neuroimaging studies. Diabetes Care. 2019;42(7):1274–83.PubMedCrossRef
7.
go back to reference Guzmán-Ramos K, Osorio-Gómez D, Bermúdez-Rattoni F. Cognitive impairment in alzheimer's and metabolic diseases: a catecholaminergic hypothesis. Neuroscience. 2022;S0306–4522(22):00271–8. Guzmán-Ramos K, Osorio-Gómez D, Bermúdez-Rattoni F. Cognitive impairment in alzheimer's and metabolic diseases: a catecholaminergic hypothesis. Neuroscience. 2022;S0306–4522(22):00271–8.
8.
go back to reference Guo M, Kang K, Wang A, Jia J, Zhang J, Wang Y, et al. Association of diabetes status with cognitive impairment in two Chinese rural communities. J Neurol Sci. 2020;415:116894.PubMedCrossRef Guo M, Kang K, Wang A, Jia J, Zhang J, Wang Y, et al. Association of diabetes status with cognitive impairment in two Chinese rural communities. J Neurol Sci. 2020;415:116894.PubMedCrossRef
9.
go back to reference Li Y, Teng D, Shi X, Qin G, Qin Y, Quan H, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ. 2020;369:m997.PubMedPubMedCentralCrossRef Li Y, Teng D, Shi X, Qin G, Qin Y, Quan H, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ. 2020;369:m997.PubMedPubMedCentralCrossRef
10.
go back to reference Hudish LI, Reusch JE, Sussel L. н╡ cell dysfunction during progression of metabolic syndrome to type 2 diabetes. J Clin Invest. 2019;129(10):4001–8.PubMedPubMedCentralCrossRef Hudish LI, Reusch JE, Sussel L. н╡ cell dysfunction during progression of metabolic syndrome to type 2 diabetes. J Clin Invest. 2019;129(10):4001–8.PubMedPubMedCentralCrossRef
11.
go back to reference Blázquez E, Hurtado-Carneiro V, LeBaut-Ayuso Y, Velázquez E, García-García L, Gómez-Oliver F, et al. Significance of brain glucose Hypometabolism, altered insulin signal transduction, and insulin resistance in several neurological diseases. Front Endocrinol. 2022;13:873301.CrossRef Blázquez E, Hurtado-Carneiro V, LeBaut-Ayuso Y, Velázquez E, García-García L, Gómez-Oliver F, et al. Significance of brain glucose Hypometabolism, altered insulin signal transduction, and insulin resistance in several neurological diseases. Front Endocrinol. 2022;13:873301.CrossRef
12.
go back to reference Pignatelli J, de Sevilla MEF, Sperber J, Horrillo D, Medina-Gomez G, Aleman IT. Insulin-like growth factor I couples metabolism with circadian activity through hypothalamic orexin neurons. Int J Mol Sci. 2022;23(9):4679.PubMedPubMedCentralCrossRef Pignatelli J, de Sevilla MEF, Sperber J, Horrillo D, Medina-Gomez G, Aleman IT. Insulin-like growth factor I couples metabolism with circadian activity through hypothalamic orexin neurons. Int J Mol Sci. 2022;23(9):4679.PubMedPubMedCentralCrossRef
13.
go back to reference Kellar D, Craft S. Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches. Lancet Neurol. 2020;19(9):758–66.PubMedCrossRef Kellar D, Craft S. Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches. Lancet Neurol. 2020;19(9):758–66.PubMedCrossRef
14.
go back to reference Tumminia A, Vinciguerra F, Parisi M, Frittitta L. Type 2 diabetes mellitus and Alzheimer's disease: role of insulin Signalling and therapeutic implications. Int J Mol Sci. 2018;19(11):3306.PubMedCentralCrossRef Tumminia A, Vinciguerra F, Parisi M, Frittitta L. Type 2 diabetes mellitus and Alzheimer's disease: role of insulin Signalling and therapeutic implications. Int J Mol Sci. 2018;19(11):3306.PubMedCentralCrossRef
15.
go back to reference Hoyer S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol. 2004;490(1–3):115–25.PubMedCrossRef Hoyer S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol. 2004;490(1–3):115–25.PubMedCrossRef
16.
go back to reference Kandimalla R, Thirumala V, Reddy PH. Is Alzheimer's disease a type 3 diabetes? A critical appraisal. Biochim Biophys Acta Mol basis Dis. 2017;1863(5):1078–89.PubMedCrossRef Kandimalla R, Thirumala V, Reddy PH. Is Alzheimer's disease a type 3 diabetes? A critical appraisal. Biochim Biophys Acta Mol basis Dis. 2017;1863(5):1078–89.PubMedCrossRef
17.
go back to reference Longde W, Ling Y, Yang H, Yi Z, Yongjun W, Xunming J, et al. Fixed-dose combination treatment after stroke for secondary prevention in China: a national community-based study. Stroke. 2015;46(5):1295–300.PubMedCrossRef Longde W, Ling Y, Yang H, Yi Z, Yongjun W, Xunming J, et al. Fixed-dose combination treatment after stroke for secondary prevention in China: a national community-based study. Stroke. 2015;46(5):1295–300.PubMedCrossRef
18.
go back to reference Pinto TCC, Machado L, Bulgacov TM, Rodrigues-Júnior AL, Costa MLG, Ximenes RCC, et al. Is the Montreal cognitive assessment (MoCA) screening superior to the Mini-mental state examination (MMSE) in the detection of mild cognitive impairment (MCI) and Alzheimer's disease (AD) in the elderly? Int Psychogeriatr. 2019;31(4):491–504.PubMedCrossRef Pinto TCC, Machado L, Bulgacov TM, Rodrigues-Júnior AL, Costa MLG, Ximenes RCC, et al. Is the Montreal cognitive assessment (MoCA) screening superior to the Mini-mental state examination (MMSE) in the detection of mild cognitive impairment (MCI) and Alzheimer's disease (AD) in the elderly? Int Psychogeriatr. 2019;31(4):491–504.PubMedCrossRef
19.
go back to reference 2. Classification and Diagnosis of Diabetes. Standards of medical Care in Diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S13–s28. 2. Classification and Diagnosis of Diabetes. Standards of medical Care in Diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S13–s28.
20.
go back to reference Priya MM, Amutha A, Pramodkumar TA, Ranjani H, Jebarani S, Gokulakrishnan K, et al. н╡-cell function and insulin sensitivity in Normal glucose-tolerant subjects stratified by 1-hour plasma glucose values. Diabetes Technol Ther. 2016;18(1):29–33.PubMedCrossRef Priya MM, Amutha A, Pramodkumar TA, Ranjani H, Jebarani S, Gokulakrishnan K, et al. н╡-cell function and insulin sensitivity in Normal glucose-tolerant subjects stratified by 1-hour plasma glucose values. Diabetes Technol Ther. 2016;18(1):29–33.PubMedCrossRef
21.
go back to reference Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–9.PubMedCrossRef Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–9.PubMedCrossRef
22.
go back to reference Hashimoto M, Tashiro H, Kobayashi T, Kuroda S, Hamaoka M, Ohdan H. Influence of higher BMI for hepatitis B- and C-related hepatocellular carcinomas. Langenbecks Arch Surg. 2017;402(5):745–55.PubMedCrossRef Hashimoto M, Tashiro H, Kobayashi T, Kuroda S, Hamaoka M, Ohdan H. Influence of higher BMI for hepatitis B- and C-related hepatocellular carcinomas. Langenbecks Arch Surg. 2017;402(5):745–55.PubMedCrossRef
23.
go back to reference Wang J, Liu Y, Zhang L, Li N, Wang C, Gao X, et al. Associations of high sensitivity C-reactive protein levels with the prevalence of asymptomatic intracranial arterial stenosis. Eur J Neurol. 2014;21(3):512–8.PubMedCrossRef Wang J, Liu Y, Zhang L, Li N, Wang C, Gao X, et al. Associations of high sensitivity C-reactive protein levels with the prevalence of asymptomatic intracranial arterial stenosis. Eur J Neurol. 2014;21(3):512–8.PubMedCrossRef
24.
go back to reference Warren JD, Bamiou DE. Prevention of dementia by targeting risk factors. Lancet. 2018;391(10130):1575.PubMedCrossRef Warren JD, Bamiou DE. Prevention of dementia by targeting risk factors. Lancet. 2018;391(10130):1575.PubMedCrossRef
25.
go back to reference Kuźma E, Hannon E, Zhou A, Lourida I, Bethel A, Levine DA, et al. Which risk factors causally influence dementia? A systematic review of Mendelian randomization studies. JAD. 2018;64(1):181–93.PubMedCrossRef Kuźma E, Hannon E, Zhou A, Lourida I, Bethel A, Levine DA, et al. Which risk factors causally influence dementia? A systematic review of Mendelian randomization studies. JAD. 2018;64(1):181–93.PubMedCrossRef
26.
go back to reference Burillo J, Marqués P, Jiménez B, González-Blanco C, Benito M, Guillén C. Insulin resistance and diabetes mellitus in Alzheimer's disease. Cells. 2021;10(5):1236.PubMedPubMedCentralCrossRef Burillo J, Marqués P, Jiménez B, González-Blanco C, Benito M, Guillén C. Insulin resistance and diabetes mellitus in Alzheimer's disease. Cells. 2021;10(5):1236.PubMedPubMedCentralCrossRef
27.
go back to reference Thankappan S, Sen S, Subramanian S, Sinha P, Purushottam M, Bharath S. Insulin resistance in patients with Alzheimer's dementia: a controlled study from India. Asian J Psychiatr. 2018;38:33–4.PubMedCrossRef Thankappan S, Sen S, Subramanian S, Sinha P, Purushottam M, Bharath S. Insulin resistance in patients with Alzheimer's dementia: a controlled study from India. Asian J Psychiatr. 2018;38:33–4.PubMedCrossRef
28.
go back to reference Hoyer S, Nitsch R. Cerebral excess release of neurotransmitter amino acids subsequent to reduced cerebral glucose metabolism in early-onset dementia of Alzheimer type. J Neural Transm. 1989;75(3):227–32.PubMedCrossRef Hoyer S, Nitsch R. Cerebral excess release of neurotransmitter amino acids subsequent to reduced cerebral glucose metabolism in early-onset dementia of Alzheimer type. J Neural Transm. 1989;75(3):227–32.PubMedCrossRef
29.
go back to reference Bingham EM, Hopkins D, Smith D, Pernet A, Hallett W, Reed L, et al. The role of insulin in human brain glucose metabolism: an 18fluoro-deoxyglucose positron emission tomography study. Diabetes. 2002;51(12):3384–90.PubMedCrossRef Bingham EM, Hopkins D, Smith D, Pernet A, Hallett W, Reed L, et al. The role of insulin in human brain glucose metabolism: an 18fluoro-deoxyglucose positron emission tomography study. Diabetes. 2002;51(12):3384–90.PubMedCrossRef
30.
go back to reference Anfossi G, Russo I, Doronzo G, Trovati M. Contribution of insulin resistance to vascular dysfunction. Arch Physiol Biochem. 2009;115(4):199–217.PubMedCrossRef Anfossi G, Russo I, Doronzo G, Trovati M. Contribution of insulin resistance to vascular dysfunction. Arch Physiol Biochem. 2009;115(4):199–217.PubMedCrossRef
31.
go back to reference Roussel R, Natali A, Balkau B, Højlund K, Sánchez G, Nolan JJ, et al. Beta-cell function is associated with carotid intima-media thickness independently of insulin resistance in healthy individuals. J Hypertens. 2016;34(4):685–91.PubMedCrossRef Roussel R, Natali A, Balkau B, Højlund K, Sánchez G, Nolan JJ, et al. Beta-cell function is associated with carotid intima-media thickness independently of insulin resistance in healthy individuals. J Hypertens. 2016;34(4):685–91.PubMedCrossRef
32.
go back to reference Zhou M, Pan Y, Jing J, Wang Y, Zhao X, Liu L, et al. Association between н╡-cell function estimated by HOMA-н╡ and prognosis of non-diabetic patients with ischaemic stroke. Eur J Neurol. 2018;25(3):549–55.PubMedCrossRef Zhou M, Pan Y, Jing J, Wang Y, Zhao X, Liu L, et al. Association between н╡-cell function estimated by HOMA-н╡ and prognosis of non-diabetic patients with ischaemic stroke. Eur J Neurol. 2018;25(3):549–55.PubMedCrossRef
33.
go back to reference Nath M, Misra S, Nair P, Kumar P. Carotid intima-media thickness and risk of mild cognitive impairment: a systematic review and meta-analysis. Acta Neurol Scand. 2022;145(2):139–50.PubMedCrossRef Nath M, Misra S, Nair P, Kumar P. Carotid intima-media thickness and risk of mild cognitive impairment: a systematic review and meta-analysis. Acta Neurol Scand. 2022;145(2):139–50.PubMedCrossRef
34.
go back to reference Ojagbemi A, Bello T, Owolabi M, Baiyewu O. Cognitive decline before and after a first-ever stroke in Africans. Acta Neurol Scand. 2021;144(3):266–74.PubMedCrossRef Ojagbemi A, Bello T, Owolabi M, Baiyewu O. Cognitive decline before and after a first-ever stroke in Africans. Acta Neurol Scand. 2021;144(3):266–74.PubMedCrossRef
35.
go back to reference Biessels GJ, Kamal A, Ramakers GM, Urban IJ, Spruijt BM, Erkelens DW, et al. Place learning and hippocampal synaptic plasticity in streptozotocin-induced diabetic rats. Diabetes. 1996;45(9):1259–66.PubMedCrossRef Biessels GJ, Kamal A, Ramakers GM, Urban IJ, Spruijt BM, Erkelens DW, et al. Place learning and hippocampal synaptic plasticity in streptozotocin-induced diabetic rats. Diabetes. 1996;45(9):1259–66.PubMedCrossRef
36.
go back to reference Skeberdis VA, Lan J, Zheng X, Zukin RS, Bennett MV. Insulin promotes rapid delivery of N-methyl-D- aspartate receptors to the cell surface by exocytosis. Proc Natl Acad Sci U S A. 2001;98(6):3561–6.PubMedPubMedCentralCrossRef Skeberdis VA, Lan J, Zheng X, Zukin RS, Bennett MV. Insulin promotes rapid delivery of N-methyl-D- aspartate receptors to the cell surface by exocytosis. Proc Natl Acad Sci U S A. 2001;98(6):3561–6.PubMedPubMedCentralCrossRef
37.
go back to reference Figlewicz DP, Szot P, Israel PA, Payne C, Dorsa DM. Insulin reduces norepinephrine transporter mRNA in vivo in rat locus coeruleus. Brain Res. 1993;602(1):161–4.PubMedCrossRef Figlewicz DP, Szot P, Israel PA, Payne C, Dorsa DM. Insulin reduces norepinephrine transporter mRNA in vivo in rat locus coeruleus. Brain Res. 1993;602(1):161–4.PubMedCrossRef
38.
go back to reference Kopf SR, Baratti CM. Effects of posttraining administration of insulin on retention of a habituation response in mice: participation of a central cholinergic mechanism. Neurobiol Learn Mem. 1999;71(1):50–61.PubMedCrossRef Kopf SR, Baratti CM. Effects of posttraining administration of insulin on retention of a habituation response in mice: participation of a central cholinergic mechanism. Neurobiol Learn Mem. 1999;71(1):50–61.PubMedCrossRef
39.
go back to reference Craft S, Raman R, Chow TW, Rafii MS, Sun CK, Rissman RA, et al. Safety, efficacy, and feasibility of intranasal insulin for the treatment of mild cognitive impairment and Alzheimer disease dementia: a randomized clinical trial. JAMA Neurol. 2020;77(9):1099–109.PubMedCrossRef Craft S, Raman R, Chow TW, Rafii MS, Sun CK, Rissman RA, et al. Safety, efficacy, and feasibility of intranasal insulin for the treatment of mild cognitive impairment and Alzheimer disease dementia: a randomized clinical trial. JAMA Neurol. 2020;77(9):1099–109.PubMedCrossRef
40.
go back to reference Barone E, Tramutola A, Triani F, Calcagnini S, Di Domenico F, Ripoli C, et al. Biliverdin reductase-a mediates the beneficial effects of intranasal insulin in Alzheimer disease. Mol Neurobiol. 2019;56(4):2922–43.PubMedCrossRef Barone E, Tramutola A, Triani F, Calcagnini S, Di Domenico F, Ripoli C, et al. Biliverdin reductase-a mediates the beneficial effects of intranasal insulin in Alzheimer disease. Mol Neurobiol. 2019;56(4):2922–43.PubMedCrossRef
41.
go back to reference Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–9.PubMedCrossRef Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–9.PubMedCrossRef
42.
go back to reference Lee SH, Park SY, Choi CS. Insulin resistance: from mechanisms to therapeutic strategies. Diabetes Metab J. 2022;46(1):15–37.PubMedCrossRef Lee SH, Park SY, Choi CS. Insulin resistance: from mechanisms to therapeutic strategies. Diabetes Metab J. 2022;46(1):15–37.PubMedCrossRef
43.
go back to reference Wang T, Lu J, Shi L, Chen G, Xu M, Xu Y, et al. Association of insulin resistance and н╡-cell dysfunction with incident diabetes among adults in China: a nationwide, population-based, prospective cohort study. Lancet Diabetes Endocrinol. 2020;8(2):115–24.PubMedCrossRef Wang T, Lu J, Shi L, Chen G, Xu M, Xu Y, et al. Association of insulin resistance and н╡-cell dysfunction with incident diabetes among adults in China: a nationwide, population-based, prospective cohort study. Lancet Diabetes Endocrinol. 2020;8(2):115–24.PubMedCrossRef
44.
go back to reference Festa A, Haffner SM, Wagenknecht LE, Lorenzo C, Hanley AJ. Longitudinal decline of н╡-cell function: comparison of a direct method vs a fasting surrogate measure: the insulin resistance atherosclerosis study. J Clin Endocrinol Metab. 2013;98(10):4152–9.PubMedPubMedCentralCrossRef Festa A, Haffner SM, Wagenknecht LE, Lorenzo C, Hanley AJ. Longitudinal decline of н╡-cell function: comparison of a direct method vs a fasting surrogate measure: the insulin resistance atherosclerosis study. J Clin Endocrinol Metab. 2013;98(10):4152–9.PubMedPubMedCentralCrossRef
45.
go back to reference Biessels GJ, Despa F. Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications. Nat Rev Endocrinol. 2018;14(10):591–604.PubMedPubMedCentralCrossRef Biessels GJ, Despa F. Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications. Nat Rev Endocrinol. 2018;14(10):591–604.PubMedPubMedCentralCrossRef
Metadata
Title
Association of β-cell function and cognitive impairment in patients with abnormal glucose metabolism
Authors
Mengyi Guo
Jiaokun Jia
Jia Zhang
Mingyue Zhou
Anxin Wang
Shengyun Chen
Xingquan Zhao
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2022
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-022-02755-6

Other articles of this Issue 1/2022

BMC Neurology 1/2022 Go to the issue